Entrada Therapeutics, Inc. Common Stock TRDA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:48:08.127Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:45:27.964041706Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:40:52.867456+00:00
Entrada Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 5.00 | 799.6% | 52.4% | |||
| 30Δ | 5.33 | 741.2% | 46.9% | |||
| 35Δ | 5.66 | 682.9% | 41.4% | |||
| 40Δ | 5.99 | 624.5% | 35.9% | |||
| 45Δ | 6.31 | 566.1% | 30.4% | |||
| 50Δ | 6.64 | 507.7% | 24.8% | |||
| 55Δ | 9.90 | 799.0% | 130.4% | 6.97 | 449.3% | 19.3% |
| 60Δ | 8.60 | 785.5% | 106.2% | 7.30 | 391.0% | 13.8% |
| 65Δ | 7.30 | 772.0% | 82.0% | 7.70 | 350.0% | 9.8% |
| 70Δ | 6.00 | 758.5% | 57.7% | 8.20 | 336.7% | 8.1% |
| 75Δ | 8.71 | 323.3% | 6.4% | |||
| 80Δ | 9.21 | 310.0% | 4.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.00
- IV
- 799.6%
- B/E move
- 52.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.33
- IV
- 741.2%
- B/E move
- 46.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.66
- IV
- 682.9%
- B/E move
- 41.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.99
- IV
- 624.5%
- B/E move
- 35.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.31
- IV
- 566.1%
- B/E move
- 30.4%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.64
- IV
- 507.7%
- B/E move
- 24.8%
55Δ
- Pseudo strike
- 9.90
- IV
- 799.0%
- B/E move
- 130.4%
- Pseudo strike
- 6.97
- IV
- 449.3%
- B/E move
- 19.3%
60Δ
- Pseudo strike
- 8.60
- IV
- 785.5%
- B/E move
- 106.2%
- Pseudo strike
- 7.30
- IV
- 391.0%
- B/E move
- 13.8%
65Δ
- Pseudo strike
- 7.30
- IV
- 772.0%
- B/E move
- 82.0%
- Pseudo strike
- 7.70
- IV
- 350.0%
- B/E move
- 9.8%
70Δ
- Pseudo strike
- 6.00
- IV
- 758.5%
- B/E move
- 57.7%
- Pseudo strike
- 8.20
- IV
- 336.7%
- B/E move
- 8.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.71
- IV
- 323.3%
- B/E move
- 6.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.21
- IV
- 310.0%
- B/E move
- 4.7%
Options history
No recorded observations
Biotechnology
TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated…
More →TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic…
More →TTRX
Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village,…
More →TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The…
More →TWST
Description unavailable
More →TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The…
More →